Small Bowel Cancer Surgery in Uberlândia-MG

Symptoms are usually nonspecific and progressive: recurrent colicky abdominal pain, bloating, nausea, and episodes of partial bowel obstruction. Occult gastrointestinal bleeding, manifesting as iron deficiency anemia of unclear cause, is a frequent warning sign. Unintentional weight loss and a palpable abdominal mass may also occur. In functioning neuroendocrine tumors, facial flushing, diarrhea, and palpitations (carcinoid syndrome) may be present. These symptoms should prompt medical evaluation, but on their own they do not confirm a cancer diagnosis.

Since conventional endoscopy and colonoscopy do not reach most of the small bowel, diagnosis relies on targeted tests: contrast-enhanced CT, CT or MRI enterography, capsule endoscopy, and double-balloon enteroscopy, which allows biopsy of the lesion. Markers such as chromogranin A and urinary 5-HIAA assist in the work-up of neuroendocrine tumors. Taken together, these findings guide surgical planning and disease staging.

Duration varies according to tumor location, extent of resection, and surgical approach, typically ranging from approximately two to five hours. Cases requiring pancreaticoduodenectomy or more extensive resections with expanded lymphadenectomy tend to take longer. The exact time can only be estimated after individual review of imaging tests and definition of the surgical plan.

Small bowel resection is performed under general anesthesia, often combined with regional anesthetic block or epidural analgesia for postoperative pain control. The anesthetic technique is defined together with the anesthesiology team, taking into account the surgical approach, the extent of surgery, and the patient's individual clinical condition.

Hospital stay usually ranges from three to seven days, and may be shorter after laparoscopic surgery with a favorable recovery, or longer after extensive resections, combined procedures such as pancreaticoduodenectomy, or in the presence of complications. Discharge depends on the return of bowel function, pain control, and the absence of signs of complications, and is determined case by case by the care team.

Some degree of abdominal pain is expected in the first few days, especially at the incision site. Pain is managed with multimodal analgesia — analgesics, anti-inflammatory drugs, and, when indicated, regional or epidural block — adjusted according to the patient's response. Laparoscopic techniques tend to be associated with less postoperative pain and faster recovery compared with the open approach, although individual response varies.

The use of an abdominal drain and nasogastric tube is decided according to the extent of resection, the location of the anastomosis, and intraoperative findings — it is not a fixed rule for every case. When used, they are usually removed within the first few days, once clinical safety criteria are met, such as reduced output and return of bowel function.

Yes, all abdominal surgery leaves a scar. With the laparoscopic approach, the incisions are small and distributed at strategic points on the abdomen. With the open approach, which is necessary in some cases depending on tumor size, location, or adhesions, the incision is more extensive, usually a midline incision. The choice of approach is individualized and discussed beforehand, considering oncologic safety and the patient's characteristics.

Time off work usually ranges from two to six weeks, depending on the surgical approach, the extent of surgery, the type of professional activity, and individual recovery progress. Jobs requiring intense physical effort usually require a longer leave than predominantly administrative activities. Return to activities is cleared gradually by the medical team.

As with any medium- to large-sized abdominal surgery, there are general risks such as bleeding, infection, and thromboembolic events. Complications more specific to this surgery include anastomotic fistula or dehiscence, prolonged paralytic ileus, adhesions, and, in extensive small bowel resections, risk of short bowel syndrome with nutrient malabsorption. Incidence and severity vary by case and should be discussed individually.

The indication for surgery depends on disease staging and the patient's clinical condition; extensive metastatic disease or severe comorbidities may limit surgery or require a primarily medical (nonsurgical) approach. Advanced adenocarcinomas may benefit from adjuvant chemotherapy, and GIST from targeted therapy with imatinib. Follow-up usually involves a multidisciplinary team — medical oncologist, radiation oncologist, and nutritionist — depending on tumor type and disease extent.